You are here

Articles

Gil Granot -Mayer Will Replace Amir Naiberg as CEO of Yeda Naiberg to head technology transfer at UCLA After 15 years at Yeda Research and Development Co. Ltd., the technology transfer arm of the Weizmann Institute of Science, five in the role of General Counsel and a decade as CEO, Amir Naiberg has accepted an offer from the University of California, Los Angeles to serve as Associate Vice Chancellor for the Office...Read more >
Weizmann Institute of Science Announces Visiting Scientist Agreement with Pfizer Inc. The Weizmann Institute of Science in Rehovot, Israel, and Yeda Research and Development Co., Ltd., its commercial arm, announced this week that they have entered a multi-year arrangement with Pfizer Inc. The arrangement will entail collaboration at the newly established National Drug Discovery Institute (DDI) in the Nancy and...Read more >
Originally printed as an advertisement feature in Nature, Vol. 533, No. 7601 (5 May 2016) One cannot predict what scientific discoveries or revolutions will be made in the laboratories of the Weizmann Institute of Science; but whatever they are, Yeda Research and Development Co. will be there to bring them to market. “When we satisfy our urge to know, we’re also benefitting humanity,” says Weizmann Institute of...Read more >
To view Yeda's Business Club 2016 Presentation click hereRead more >
A protocol that arose from Weizmann Institute of Science research has led to US Food and Drug Administration approval of a new biological drug for the treatment of a certain form of lung cancer. This is the third cancer drug to be developed on the basis of studies conducted by the Weizmann Institute’s Prof. Michael Sela, of the Department of Immunology, and his colleagues. All three drugs are antibodies that block a...Read more >
EAU TV spoke to Mark Emberton, UCL, and Eva Johannsen, University of Gothenburg at EAU16 about the use and limitations of active surveillance, how it affects quality of life, and a new drug that facilitates better prostate treatment. http://youtu.be/3HXAtamsGDwRead more >
Darmstadt, Germany, and Rehovot, Israel, February 16, 2016 – Merck, a leading science and technology company, today extended the partnership with Weizmann Institute of Science, Rehovot, Israel, of by signing a new framework agreement, building on a successful innovation partnership of almost four decades. Innovation was key for Merck’s now nearly 350 years of history and will play the same crucial role in the...Read more >
Darmstadt, Germany, and Rehovot, Israel, February 16, 2016 – Merck, a leading science and technology company, announced that the Weizmann Institute conferred the renowned Weizmann Award in the Sciences and Humanities to Karl-Ludwig Kley, CEO and Chairman of the Executive Board and of Merck. “It is particularly important to us to acknowledge and honor your support and friendship of Israel and of the Weizmann...Read more >
Tel Aviv -- February 1, 2016: NewCO2Fuels (NCF), an Israeli start-up which transforms CO2 emissions into a clean fuel that can be sold as a commodity at competitive prices, was anno unced as the winner of the "Innovation Potential" category during the 2015 International Quality Inno vation of the Year Awards Ceremony this month in Tallinn, Estonia. NCF receives award of Innovation Potential The International Quality...Read more >
Weizmann Institute Drug, TOOKAD® Soluble, Approved for Prostate Cancer Therapy in Mexico A therapy invented at the Weizmann Institute of Science and clinically developed in collaboration with Steba Biotech (Luxembourg) has been approved by Cofepris, Mexico’s health authority, for the focal treatment of early-stage prostate cancer. The therapy involves a laser and a novel drug, TOOKAD® Soluble. A successful Phase III...Read more >
NCF’s technology, which captures CO2 emissions and turns them into fuel, may offer an alternative to cutting back on greenhouse gases DAPHNE ROUSSEAU. 2015 The company called NewCO2Fuels, or NCF, has been developing its own version of a technology that allows heat-trapping carbon dioxide emissions to be captured and recycled back into useable fuel. It sounds complicated — and it is — but the company’s founders say...Read more >
Tech Republic, 2 December http://www.techrepublic.com/article/how-new-fuel-tech-could-drastically-... The stakes are high this week as world leaders convene in Paris for the United Nations Conference of Parties ( COP21 ), intended to create a broad multilateral agreement limiting greenhouse gas emissions. David Banitt, founder and CEO of NewCO2Fuels, is a technologist, not an environmentalist. While solutions to...Read more >
ImmunArray Ltd announces the Launch of the SLE-key™ Rule Out test to be run out of VERACIS the Company’s Service Laboratory beginning in March 2015, in Richmond, Virginia Richmond, VA and Rehovot, Israel. February 12, 2015 – ImmunArray, developer of the iCHIP™, a groundbreaking in-vitro auto-antibody profiling platform is pleased to announce the launch of their first commercial diagnostic product, SLE-key™ Rule Out...Read more >
To view Yeda's Business Club 2015 Presentation click here To view Yeda's Business Club 2015 Photos click hereRead more >
To view Yeda's Business Club 2014 Presentation click hereRead more >
XL-protein from Germany and Yeda, the commercial arm of the Weizmann Institute of Science, have announced the signing of a collaboration agreement for the commercial exploitation of an improved interferon molecule that was developed by scientists from the Institute and from XL-protein. The agreement states that Yeda will also represent the XL-protein scientists and may grant licenses to different companies for the...Read more >
An Israeli-Australian venture will use solar technology developed at the Weizmann Institute of Science to reduce carbon dioxide emissions from the burning of brown coal. The venture has been recently launched in Israel by NewCO2Fuels Ltd., a subsidiary of the Australian company Greenearth Energy Ltd., which has acquired an exclusive worldwide license for the solar technology from Yeda, the Weizmann Institute’s...Read more >
3i to Develop Microscopes of the Future Based on Weizmann Institute Inventions Yeda, the technology transfer arm of the Weizmann Institute of Science, has signed a license agreement with ’3i.’ Other microscopy systems based on Weizmann research are being sold by ‘Idea Bio-Medical’ The imaging potential of cutting-edge microscopes will soon be expanded thanks to Weizmann Institute inventions. A licensing agreement...Read more >
Prolor received approval for a new patent by the Patent Authority in the U.S. for its RPEG platform. Prolor’s medicine for obesity and Type-2 diabetes is based on this platform. Link for announcement in Maya: http://maya.tase.co.il/bursa/report.asp?report_cd=774498Read more >
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) and LifeMap Sciences, Inc. announce the launch of MalaCards, a new database of human diseases that is based on their leading GeneCards® platform. MalaCards ( www.malacards.org/ ) contains computerized “cards” classifying information relating to a wide array of human diseases. This novel research tool will aid researchers in studying the roles of genes...Read more >